 The proposed randomized clinical trial aims to assess both the safety and efficacy of atypical antipsychotic agents in antipsychotic-naive aggressive children with various childhood psychiatric disorders during 12 weeks of prospective, randomized treatment with olanzapine Zyprexa, risperidone Risperdal or aripiprazole Abilify. 